Zeo Scientifix, Inc last reported quarterly results on Jul 8, 2026, for Q2 FY2026 (the quarter ended Apr 30, 2026): revenue of $2.6 million (+124.6% year over year) and diluted EPS of -$0.02. It usually reports 69 days after a quarter ends. Based on that pattern, the next release is estimated for around Oct 8, 2026.
Results for Q3 FY2026, the quarter ending around Jul 31, 2026. Expected on a Thursday. Based on how many days after a quarter ends the company has reported recently. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 69 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Jul 8, 2026
69 days after quarter end
|
Q2 FY2026
ended Apr 30, 2026
|
3
+124.6%
|
-0
+89.6%
|
-0.02
+90.9%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZEOX (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Davie, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1557376
- Former names
- Organicell Regenerative Medicine, Inc. (until Jan 29, 2024); Biotech Products Services & Research, Inc. (until Jun 15, 2018); BESPOKE TRICYCLES INC (until Sep 14, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.